- Home
- DNP vs RARE Comparison
DNP vs RARE Comparison
Compare DNP & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNP
- RARE
- Stock Information
- Founded
- DNP 1986
- RARE 2010
- Country
- DNP United States
- RARE United States
- Employees
- DNP N/A
- RARE N/A
- Industry
- DNP Investment Managers
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- DNP Finance
- RARE Health Care
- Exchange
- DNP Nasdaq
- RARE Nasdaq
- Market Cap
- DNP 3.7B
- RARE 3.2B
- IPO Year
- DNP N/A
- RARE 2014
- Fundamental
- Price
- DNP $10.18
- RARE $35.17
- Analyst Decision
- DNP
- RARE Strong Buy
- Analyst Count
- DNP 0
- RARE 13
- Target Price
- DNP N/A
- RARE $87.69
- AVG Volume (30 Days)
- DNP 479.6K
- RARE 1.3M
- Earning Date
- DNP 01-01-0001
- RARE 11-04-2025
- Dividend Yield
- DNP 7.88%
- RARE N/A
- EPS Growth
- DNP N/A
- RARE N/A
- EPS
- DNP 2.30
- RARE N/A
- Revenue
- DNP $154,887,179.00
- RARE $610,159,000.00
- Revenue This Year
- DNP N/A
- RARE $19.65
- Revenue Next Year
- DNP N/A
- RARE $23.35
- P/E Ratio
- DNP $4.26
- RARE N/A
- Revenue Growth
- DNP 3.30
- RARE 26.77
- 52 Week Low
- DNP $8.69
- RARE $25.81
- 52 Week High
- DNP $10.04
- RARE $53.47
- Technical
- Relative Strength Index (RSI)
- DNP 64.34
- RARE 63.44
- Support Level
- DNP $10.12
- RARE $33.94
- Resistance Level
- DNP $10.22
- RARE $35.95
- Average True Range (ATR)
- DNP 0.08
- RARE 1.32
- MACD
- DNP 0.02
- RARE 0.16
- Stochastic Oscillator
- DNP 78.13
- RARE 82.97
About DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.